BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38110664)

  • 21. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
    Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
    Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/β-catenin signaling regulation.
    Shome R; Ghosh SS
    Cell Oncol (Dordr); 2021 Apr; 44(2):405-422. PubMed ID: 33398673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.
    Pai JT; Chen XH; Leu YL; Weng MS
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.
    Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y
    Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin.
    Grasset EM; Dunworth M; Sharma G; Loth M; Tandurella J; Cimino-Mathews A; Gentz M; Bracht S; Haynes M; Fertig EJ; Ewald AJ
    Sci Transl Med; 2022 Aug; 14(656):eabn7571. PubMed ID: 35921474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
    Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
    Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
    [No Abstract]   [Full Text] [Related]  

  • 27. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells.
    Wang M; Zhang J; Huang Y; Ji S; Shao G; Feng S; Chen D; Zhao K; Wang Z; Wu A
    Med Sci Monit; 2017 Aug; 23():3904-3912. PubMed ID: 28802099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
    Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
    Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pomegranate peel extract inhibits expression of β-catenin, epithelial mesenchymal transition, and metastasis in triple negative breast cancer cells.
    Bagheri M; Fazli M; Saeednia S; Kor A; Ahmadiankia N
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(7):86-91. PubMed ID: 29974851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hydnocarpin inhibits malignant progression of triple negative breast cancer via CNOT4-mediated ubiquitination and degradation of YAP].
    Ou HL; Wu H; Ren YL; Si Y; Duan ZQ; Liu XW
    Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(16):4483-4492. PubMed ID: 37802875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model.
    Guo Y; Fan Y; Pei X
    Cancer Med; 2020 Apr; 9(7):2564-2578. PubMed ID: 32037729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
    Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
    Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
    Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression.
    Park J; Tacam MJ; Chauhan G; Cohen EN; Gagliardi M; Iles LR; Ueno NT; Battula VL; Sohn YK; Wang X; Kim HS; Krishnamurthy S; Fowlkes NW; Green MM; Bartholomeusz GA; Tripathy D; Reuben JM; Bartholomeusz C
    Breast Cancer Res Treat; 2021 Sep; 189(2):333-345. PubMed ID: 34241740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
    Lou L; Yu Z; Wang Y; Wang S; Zhao Y
    Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.